What question did this study set out to answer?

To evaluate the effectiveness of cTBS in improving upper limb function after stroke within 90 days of onset.

January 22, 2026Open Access

B-STARS2: Early contralesional continuous theta burst stimulation (cTBS) to promote upper limb recovery after stroke – Rationale and design of a phase-3 multicentre, randomised, sham-controlled, clinical trial

Key Points

To evaluate the effectiveness of cTBS in improving upper limb function after stroke within 90 days of onset.
Conduct a multicentre, double-blind, randomised, sham-controlled trial.
Assign 454 patients with unilateral upper limb paresis to active or sham cTBS combined with therapy.
Deliver 10 sessions of cTBS over the contralesional primary motor cortex, starting within 3 weeks of stroke.
Primary outcome measured by Fugl-Meyer Upper Extremity (FM-UE) score at 90 days post-stroke.
Minimal detectable effect aimed for at least 6.6 points improvement on the FM-UE scale.
Evaluate secondary outcomes including various functional and quality of life assessments at 90 days and 12 months.

Abstract

Abstract Rationale Many stroke survivors have persisting upper limb impairment. In a phase-2 trial, early contralesional continuous theta burst stimulation (cTBS) improved upper limb recovery and functional outcome after stroke, but confirmation of this benefit in a larger, phase-3 trial is required before this can be recommended as standard of care. Aim We aim to assess whether 10 sessions of cTBS of the contralesional primary motor cortex, combined with regular care upper limb training, started within 3 weeks after stroke onset and continued for 2 weeks, reduces upper limb impairment at 90 days after stroke as compared to sham stimulation. Methods and design We will perform a multicentre, double-blind, randomised, sham-controlled, clinical trial. Patients with ischaemic stroke or intracerebral haemorrhage and unilateral upper limb paresis will be assigned to receive 10 daily sessions of active or sham cTBS, delivered over the contralesional primary motor cortex, combined with regular care upper limb therapy and started within 3 weeks after stroke onset. Outcomes The primary outcome is the score of the Fugl-Meyer Upper Extremity (FM-UE) assessment at 90 days after stroke. Secondary outcomes are the FM-UE score at 12 months after stroke and scores on the Action Research Arm Test, Nine Hole Peg Test, modified Rankin Scale, Barthel Index, hand, participation and overall recovery sections of the Stroke Impact Scale and the EuroQol-5D-5L at 90 days and 12 months post-stroke. Additionally, cost-effectiveness, length of stay at the rehabilitation centre, and ipsilesional and contralesional excitability are assessed. Sample size We will randomise 454 participants 1:1 to active or sham cTBS. The sample size is based on a minimal detectable effect of 6.6 points on the FM-UE scale. Discussion If cTBS treatment leads to a cost-effective and clinically meaningful additional recovery of at least 6.6 points on the FM-UE scale at 90 days after stroke, then cTBS treatment can be recommended as standard of care.

Read Full Paperexternally

Bookmark

View Full Paper

Cite This Study

Vink et al. (Thu,) studied this question.

synapsesocial.com/papers/6971be2c642b1836717e2d8d https://doi.org/https://doi.org/10.1093/esj/23969873251355937

Bookmark

View Full Paper